Search clinical trials for: Transition phase

Total 20140 results

Bristol-Myers Squibb

Recruiting

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Canada, United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Bladder Cancer

China
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
University Hospital, Geneva

Recruiting

Electroencephalographic Signatures of Neuropsychiatric Fluctuations in Parkinson's Disease (Transition)

Parkinson Disease

Switzerland
Fusion Pharmaceuticals Inc.
AstraZeneca

Not yet recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
University of Pittsburgh
Agency for Healthcare Research and Quality (AHRQ)

Recruiting

Pilot Testing PICTURE-THIS

Critical Care | Health Services | Transitional Care | Post-intensive Care Syndrome

United States
Hansoh BioMedical R&D Company

Not yet recruiting

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Non-Small Cell Lung Cancer | Solid Tumor

China
Volastra Therapeutics, Inc.

Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Gastric Adenocarcinoma | Uterine Carcinosarcoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Transitional Cell Carcinoma of Bladder | Colorectal Adenocarcinoma | Gastroesophageal Junction... and other conditions

United States
Novartis Pharmaceuticals

Recruiting

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA)

Follicular Lymphoma (FL)

Australia, Korea, Republic of, Spain, Singapore, Poland, Taiwan, Hungary, Czechia, Romania, Slovakia
Hospices Civils de Lyon

Not yet recruiting

Peer-supporting for Teenagers With Cystic Fibrosis in the Transition of Care From Paediatric to Adult Services (MUKADO)

Cystic Fibrosis

France
AdventHealth
Jazz Pharmaceuticals

Recruiting

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Metastatic Cancer | Urothelial Carcinoma

United States
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
M.D. Anderson Cancer Center

Recruiting

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Metastatic Cancer | Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
AstraZeneca

Recruiting

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
NYU Langone Health
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity

Children With Medical Complexity (CMC)

United States
University of Alabama at Birmingham
University of Texas Southwestern Medical Center

Recruiting

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

Kidney Stone

United States
Sheba Medical Center

Recruiting

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Metastatic Urothelial Carcinoma

Israel
Inhibrx, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Gastric Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Urothelial Carcinoma

United States
Hospices Civils de Lyon

Not yet recruiting

Development and Evaluation of a Patient-centered Transition Program for Stroke Patients, Combining Case Management and Access to an Internet Information Platform (NAVISTROKE)

Stroke
University of Southern California
National Cancer Institute (NCI)

Recruiting

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Prostate Cancer | Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Novartis Pharmaceuticals

Completed

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA)

Non-Hodgkin Lymphoma

Japan, Spain, Germany, Australia, Austria, Canada, Italy, Norway, United States, United Kingdom, Finland, France, Denmark, Netherlands
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
Bayer

Active, not recruiting

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)

Urothelial Carcinoma

United States, Korea, Republic of, Japan, Germany, Italy, Spain, Austria, France
USRC Kidney Research
GlaxoSmithKline

Completed

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease (ROQ-IT)

Renal Insufficiency, Chronic | Anemia | Renal Anemia

United States
South Metropolitan Health Service
Telix Pharmaceuticals (Innovations) Pty Limited

Completed

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients (ZiPUP)

Urothelial Carcinoma

Australia
TJ Biopharma Co., Ltd.

Withdrawn

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

First-line Non-small-cell Lung Cancer | First-line Urothelial Carcinoma | Second-line Urothelial Carcinoma | Second-line Melanoma

China
Carisma Therapeutics Inc

Active, not recruiting

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Adenocarcinoma | Stomach Neoplasms | Cancer | Breast Cancer | Head and Neck Cancer | Carcinoma, Hepatocellular | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Carcinoma, Ovarian Epithelial | Carcinoma, Transitional Cell | Breast Neoplasm | Prostate Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer and other conditions

United States
Ikena Oncology
Bristol-Myers Squibb

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Neoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditions

United States
HiberCell, Inc.
Covance

Terminated

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Clear Cell Renal Cell Carcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Colo-rectal Cancer | Transitional Cell Carcinoma of the Bladder | Other Solid Tumors

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Active, not recruiting

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Bladder Cancer | Urothelial Carcinoma | Metastatic Bladder Cancer

United States
BeiGene

Completed

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Healthy | Male

United States
RemeGen Co., Ltd.

Completed

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Dr. Reddy's Laboratories Limited
PPD

Completed

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (RI-01-007)

Rheumatoid Arthritis

United States
Scynexis, Inc.

Suspended

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (MARIO)

Candidemia | Candidiasis, Invasive

United States, Korea, Republic of, Greece, Canada, France, Belgium, Germany, Italy, Spain, South Africa, Bulgaria, Israel
University Ghent
Institut de Recherche en Sciences de la Sante, Burkina Faso; Centre Muraz; University...

Completed

Dietary Rehabilitation in Severely Acutely Malnourished Children

Severe Acute Malnutrition | Kwashiorkor | Marasmus | Nutritional Edema

Burkina Faso
University Ghent
Institut de Recherche en Sciences de la Sante, Burkina Faso; Centre Muraz; University...

Completed

Effectiveness of Four Transition Dietary Regimens in the Hospital Management of Children With Kwashiorkor.

Severe Acute Malnutrition | Kwashiorkor | Nutritional Edema

Burkina Faso
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
Mirati Therapeutics Inc.

Terminated

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma Bladder | Urothelial Carcinoma | Urothelial Carcinoma Ureter | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Urethra

United States
University of Michigan
National Institute of Mental Health (NIMH); University of Wisconsin, Madison; SIMmersion, LLC

Completed

Modifying (Phase I) and Evaluating (Phase II) Virtual Reality Job Interview Training for Youth in Transition

Autism Spectrum Disorder

United States
Universidad de La Frontera

Completed

Hybrid Cardiac Rehabilitation Trial (HYCARET)

Coronary Artery Disease | Acute Coronary Syndrome

Chile
The Methodist Hospital Research Institute

Active, not recruiting

Phase Ib of L-NMMA and Pembrolizumab

Non-Small Cell Lung Cancer | DNA Repair-Deficiency Disorders | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma Bladder | Classical Hodgkin Lymphoma | Malignant Melanoma

United States
Ludwig Institute for Cancer Research
Krankenhaus Nordwest

Completed

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Melanoma | Sarcoma | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Transitional Cell Carcinoma | Prostate Cancer | Ovarian Carcinoma | Gastrointestinal Stromal Tumor (GIST)

Germany
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
Guru P. Sonpavde
QED Therapeutics, Inc.

Withdrawn

Phase I BLASST-3 Trial ((BLASST)-3)

Bladder Cancer | Bladder Transitional Cell Carcinoma | Fibroblast Growth Factor Receptor
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
University Hospital Tuebingen
Bayer

Withdrawn

Reveal Transition - A Mechanistic Study in Transition / Stabilized Phase of CAD (RevealTrans)

Cardiovascular Diseases

Germany
Noah Hahn, M.D.
Hoosier Cancer Research Network; Achieve Life Sciences

Completed

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

United States
Université du Québec à Trois-Rivières
Public Health Agency of Canada (PHAC); Canada Research Chairs Endowment of... and other collaborators

Active, not recruiting

Supporting the Transition to and Engagement in Parenthood (STEP)

Mental Health Issue | Trauma, Psychological | Maternal Distress | Prenatal Stress

Canada

Search clinical trials for: Transition phase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations